These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7731675)

  • 1. The biology of Abl during hemopoietic stem cell differentiation and development.
    Chung SW; Wong PM
    Oncogene; 1995 Apr; 10(7):1261-8. PubMed ID: 7731675
    [No Abstract]   [Full Text] [Related]  

  • 2. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR; Gerlach MJ; Koh EY; Daley GQ
    Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
    Carlesso N; Griffin JD; Druker BJ
    Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
    Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ
    Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor.
    Pierce A; Spooncer E; Ainsworth S; Whetton AD
    Oncogene; 2002 May; 21(19):3068-75. PubMed ID: 12082538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells.
    Jena N; Deng M; Sicinska E; Sicinski P; Daley GQ
    Cancer Res; 2002 Jan; 62(2):535-41. PubMed ID: 11809706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transduction by wild-type and leukemogenic Abl proteins.
    Raitano AB; Whang YE; Sawyers CL
    Biochim Biophys Acta; 1997 Dec; 1333(3):F201-16. PubMed ID: 9426204
    [No Abstract]   [Full Text] [Related]  

  • 11. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis.
    Skorski T; Nieborowska-Skorska M; Szczylik C; Kanakaraj P; Perrotti D; Zon G; Gewirtz A; Perussia B; Calabretta B
    Cancer Res; 1995 Jun; 55(11):2275-8. PubMed ID: 7757976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abl tyrosine kinase in signal transduction and cell-cycle regulation.
    Wang JY
    Curr Opin Genet Dev; 1993 Feb; 3(1):35-43. PubMed ID: 8453272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.
    Nakamura Y; Yujiri T; Nawata R; Tagami K; Tanizawa Y
    Oncogene; 2005 Nov; 24(51):7592-8. PubMed ID: 16044153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular perspective: c-Abl tyrosine kinase.
    Goodsell DS
    Stem Cells; 2006 Jan; 24(1):209-10. PubMed ID: 16449631
    [No Abstract]   [Full Text] [Related]  

  • 15. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z; Sampath J; Fukuda S; Pelus LM
    Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular perspective: c-Abl tyrosine kinase.
    Goodsell DS
    Oncologist; 2005 Oct; 10(9):758-9. PubMed ID: 16249357
    [No Abstract]   [Full Text] [Related]  

  • 19. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
    Cortez D; Stoica G; Pierce JH; Pendergast AM
    Oncogene; 1996 Dec; 13(12):2589-94. PubMed ID: 9000132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.